This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Merck has also decided to end the favezelimab clinical development program
First and only PARP inhibitor to improve overall survival in early breast cancer
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
